NYU Langone Health ranked No. 1 in the Nation for Quality and Patient Safety

Our Bureau

NYU Langone Health has once again been named No. 1 in the nation for quality and patient safety by Vizient, Inc., a leading healthcare performance improvement organization that determines its rankings based on mortality and infection rates, patient experience scores, and other critical quality measures. At a ceremony hosted by Vizient in Las Vegas last evening, NYU Langone received the Bernard A. Birnbaum, MD, Quality Leadership Award for superior performance in patient care and the Ambulatory Quality and Accountability Award for excellence in outpatient care.

NYU Langone Hospital—Long Island was also named No. 1 nationally in the Birnbaum Quality Leadership ranking of specialized complex care medical centers, and NYU Langone Hospital—Brooklyn also ranked among the top 10 in its category. Vizient determines the rankings among participating institutions and counts among its membership 97 percent of academic medical centers in the United States.

“Where patients get their care matters. Each day we have the opportunity to make a difference in someone’s life and we take that responsibility seriously, striving for excellence in everything we do,” said Robert I. Grossman, MD, CEO of NYU Langone Health and dean of NYU Grossman School of Medicine. “I’m grateful to our dedicated teams who achieved this national recognition, working tirelessly to deliver the best outcomes and one consistently high standard of care for our patients.”

The Bernard A. Birnbaum, MD, Quality Leadership Award, named in memory of NYU Langone’s former chief of hospital operations, ranks NYU Langone hospitals in Manhattan as No. 1 out of 116 comprehensive academic medical centers for the second year in a row. The award recognizes NYU Langone for delivering high-quality care based on safety, mortality, effectiveness, efficiency, patient-centeredness, and equity.

“For a campus with such high volume and complex cases, this award provides a wonderful moment to take pride in our work,” said Fritz François, MD, executive vice president and vice dean, chief of hospital operations. “Bernie Birnbaum dedicated his career at NYU Langone to improving quality, safety, and patient experience and I can think of no better way to honor his memory.”

NYU Langone Hospital—Long Island ranked No. 1 among 154 large specialized complex medical centers in the nation, rising to the top spot after ranking fifth last year.

“Ranking not just number one on Long Island, or in New York, but first in the nation is incredible recognition of the unparalleled care we provide at NYU Langone Hospital—Long Island,” said Joseph J. Greco, MD, executive vice president and chief of hospital operations. “Our patients are the greatest beneficiary of achievements like this and we’re so grateful they have put their trust in us.”

NYU Langone Hospital—Brooklyn ranked No. 7 in the nation in the same category, continuing to stand out in a borough where it remains the only hospital with an “A” rating on the Leapfrog Hospital Safety Grade and with Magnet-recognition for excellence in nursing by the American Nurses Credentialing Center.

“As the only hospital in Brooklyn recognized as a Vizient 2023 Top Performer, NYU Langone Hospital—Brooklyn is a beacon for exceptional healthcare,” said Bret J. Rudy, MD, executive vice president and chief of hospital operations. “We are proud to serve the diverse communities of Brooklyn and provide top quality and safety outcomes.”

Author

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 Trial

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) and Seagen Inc. (Nasdaq: SGEN) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV® (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab) versus chemotherapy in patients with previously untreated locally advanced or […]
Astellas Pharma and Seagen Logos

Subscribe Now